Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Download Uses Of Epoetin For Oncology full books in PDF, epub, and Kindle. Read online Uses Of Epoetin For Oncology ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author :
Publisher :
ISBN 13 :
Total Pages : 352 pages
Book Rating : 4.5/5 (959 download)
Download or read book Uses of Epoetin for Anemia in Oncology written by and published by . This book was released on 2001 with total page 352 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Jerome Seidenfeld
Publisher :
ISBN 13 : 9781587630422
Total Pages : 0 pages
Book Rating : 4.6/5 (34 download)
Download or read book Uses of Epoetin for Anemia in Oncology written by Jerome Seidenfeld and published by . This book was released on 2001 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author :
Publisher :
ISBN 13 :
Total Pages : 330 pages
Book Rating : 4.:/5 (762 download)
Download or read book Uses of Epoetin for Oncology written by and published by . This book was released on 2001 with total page 330 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Uses of Epoetin for Anemia in Oncology written by and published by . This book was released on 2001 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Carsten Bokemeyer
Publisher : Elsevier Science Health Science Division
ISBN 13 : 9780080445755
Total Pages : 304 pages
Book Rating : 4.4/5 (457 download)
Download or read book Anaemia in Cancer written by Carsten Bokemeyer and published by Elsevier Science Health Science Division. This book was released on 2004-11 with total page 304 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Mohammad Resa Nowrousian
Publisher : Springer Science & Business Media
ISBN 13 : 3709176581
Total Pages : 524 pages
Book Rating : 4.7/5 (91 download)
Download or read book Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology written by Mohammad Resa Nowrousian and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 524 pages. Available in PDF, EPUB and Kindle. Book excerpt: Anemia is a frequent complication of cancer and its treatment. A number of clinical studies shows that the impact of anemia is much greater than previously thought. Beyond clinical symptoms, anemia significantly impairs physical and metabolic functions as well as patients' activity, well-being and quality of life. Life expectancy is also affected. In this book, written by a group of outstanding international experts, the current knowledge on anemia in cancer and its treatment with rhEPO is presented. Future developments are also discussed. Based on a broad spectrum of topics, the book describes the scientific and clinical aspects of anemia in various fields of oncology and gives diagnostic and therapeutic recommendations on when and how to use rhEPO.
Author :
Publisher :
ISBN 13 :
Total Pages : 8 pages
Book Rating : 4.:/5 (469 download)
Download or read book Uses of Epoetin for Anemia in Oncology written by and published by . This book was released on 2001 with total page 8 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : U. S. Department of Health and Human Services
Publisher : CreateSpace
ISBN 13 : 9781490528267
Total Pages : 272 pages
Book Rating : 4.5/5 (282 download)
Download or read book Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update written by U. S. Department of Health and Human Services and published by CreateSpace. This book was released on 2013-06-24 with total page 272 pages. Available in PDF, EPUB and Kindle. Book excerpt: Anemia, a deficiency in the concentration of hemoglobin-containing red blood cells, is prevalent among cancer patients, depending on the type of malignancy and treatment. Transfusion is one option for treating anemia related to cancer and cancer treatment. Transfusion carries a very low risk of infection and other adverse events, including transfusion reactions, alloimmunization, overtransfusion, and immune modulation with theoretically possible adverse effects on tumor growth. (For example, adverse events that could be definitively attributed to transfusions were not reported in any trial included in this review for adverse event outcomes.) Erythropoietin, a hormone produced in the kidney, is the major regulator of red blood cell production (erythropoiesis). Commercially produced recombinant human erythropoietins have been extensively studied and used clinically for more than a decade to treat anemia in association with various diseases, reducing the need for transfusion. These include epoetin alfa (Epogen®, Procrit®) and epoetin beta (not available in the United States); they have similar clinical efficacy. Darbepoetin alfa (Aranesp®), more recently developed, produces a similar physiologic response and is commercially available in the United States. All erythropoietic-stimulating agents (ESAs) increase the number of red blood cells within about 2 to 3 weeks when given to individuals with functioning erythropoiesis. The development of intensified antineoplastic therapies has increased the risk for anemia and the likelihood of treatment. Initially, adverse effects that could be conclusively attributed to erythropoietin treatment had been reported in very few patients; more recently, randomized controlled trials have reported increased incidence of thrombotic events and reduced survival. This resulted in multiple pooled analyses of ESA trial data over several years, as well as regulatory actions by the U.S. Food and Drug Administration (FDA). The Blue Cross and Blue Shield Association Technology Evaluation Center, an Evidence-based Practice Center funded by the Agency for Healthcare Research and Quality, conducted a systematic review of epoetin use in oncology (2001) and a comparative effectiveness review, “Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment” (2006). This update includes new evidence that was not available in 2006. In particular, we incorporated results from a recently published meta-analysis3 of individual patient data from studies enrolling more than 50 patients per arm; inclusion for this update was limited to studies of similar size. In contrast, the previous report2 included studies enrolling 10 or more patients per arm. Sensitivity analyses performed for each outcome with data from studies excluded because of size showed no differing results. This report addresses the following Key Questions: Key Question 1. What are the comparative benefits and harms of erythropoiesis-stimulating agent strategies and non-ESA strategies to manage anemia in patients undergoing chemotherapy or radiation for malignancy (excluding myelodysplastic syndrome and acute leukemia)? Key Question 2. How do alternative thresholds for initiating treatment compare regarding their effect on the benefits and harms of erythropoietic stimulants? Key Question 3. How do different criteria for discontinuing therapy or for optimal duration of therapy compare regarding their effect on the benefits and harms of erythropoietic stimulants?
Author :
Publisher :
ISBN 13 :
Total Pages : 112 pages
Book Rating : 4.3/5 (121 download)
Download or read book Recombinant Erythropoietin written by and published by . This book was released on 1990 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Ajay K. Singh
Publisher : Academic Press
ISBN 13 : 0080920462
Total Pages : 534 pages
Book Rating : 4.0/5 (89 download)
Download or read book Textbook of Nephro-Endocrinology written by Ajay K. Singh and published by Academic Press. This book was released on 2009-01-12 with total page 534 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Textbook of Nephro-Endocrinology is the definitive translational reference in the field of nephro-endocrinology, investigating both the endocrine functions of the kidneys and how the kidney acts as a target for hormones from other organ systems. It offers researchers and clinicians expert, gold-standard analyses of nephro-endocrine research and translation into the treatment of diseases such as anemia, chronic kidney disease (CKD), rickets, osteoporosis, and, hypoparathyroidism. Investigates both the endocrine functions of the kidneys and how the kidney acts as a target for hormones from other organ systems Presents a uniquely comprehensive and cross-disciplinary look at all aspects of nephro-endocrine disorders in one reference work Clear translational presentations by the top endocrinologists and nephrologists in each specific hormone or functional/systems field
Author : Stephen J. Withrow
Publisher : Elsevier Health Sciences
ISBN 13 : 1437723624
Total Pages : 775 pages
Book Rating : 4.4/5 (377 download)
Download or read book Withrow and MacEwen's Small Animal Clinical Oncology written by Stephen J. Withrow and published by Elsevier Health Sciences. This book was released on 2012-11-13 with total page 775 pages. Available in PDF, EPUB and Kindle. Book excerpt: With a unique focus on the most effective interventional techniques, Withrow & MacEwen's Small Animal Clinical Oncology, 5th Edition tells the full story of cancer in dogs and cats - what it is, how to diagnose it, and how to treat many of the most common cancers encountered in clinical practice. Nearly 500 color photographs, diagrams, x-rays, and gross views depict the clinical manifestations of various cancers. This edition covers the latest advances in clinical oncology, including chemotherapy, surgical oncology, and diagnostic techniques. With contributions from 65 veterinary oncology experts, this authoritative reference is a must-have for current, evidence-based therapeutic strategies on canine and feline oncology. "I really love this book. If you are interested in veterinary oncology, have a flick through this book online or at a conference when you get the chance. I hope that you agree with me that this is the definitive oncology reference source for the early 21st century and that you feel compelled to buy it. Your patients will thank you for it." Reviewed by: Gerry Polton MA VetMB MSc(Clin Onc) DipECVIM-CA(Onc) MRCVS, UK Date: July 2014 Cutting-edge information on the complications of cancer, pain management, and the latest treatment modalities prepares you to diagnose and treat pets with cancer rather than refer cases to a specialist. A consistent format for chapters on body system tumors includes coverage of incidence and risk factors, pathology, natural behavior of tumors, history and clinical signs, diagnostic techniques and workup, treatment options, and prognosis for specific malignancies. A systems approach to the diagnosis and management of cancer facilitates access to information about the many malignancies affecting small animal patients. Nearly 500 color images provide accurate depictions of specific diseases and procedures. Helpful drug formularies provide quick access to information on indications, toxicities, and recommended dosages for chemotherapeutic and analgesic drugs used in cancer treatment. Expert contributors provide in-depth coverage of the most current information in his or her respective specialty in veterinary oncology. Chemotherapy protocols are included when case studies prove clinical efficacy. Discussion of compassion and supportive care for the management of pain, nutritional needs, and grief includes methods for handling the pet's pain and nutritional complications as well as the pet owner's grief when treatment is not successful. Thoroughly UPDATED chapters cover the most recent changes in the clinical management of melanoma, mast cell tumors, tumors of the skeletal system, tumors of the endocrine system, tumors of the mammary gland, urinary cancers, nervous system cancers, lymphoma, and histiocytic diseases. NEW Clinical Trials and Developmental Therapeutics chapter discusses the various phases of clinical trials as well as current challenges and opportunities in oncology drug development. NEW! A focus on the best recommended treatment options highlights therapeutic strategies that have been vetted by veterinary oncology experts. NEW co-author Dr. Rodney L. Page adds his valuable perspective, expertise, and research experience.
Author : American Society of Clinical Oncology. Annual Meeting
Publisher :
ISBN 13 :
Total Pages : 1140 pages
Book Rating : 4.:/5 (1 download)
Download or read book 40th Annual Meeting of the American Society of Clinical Oncology written by American Society of Clinical Oncology. Annual Meeting and published by . This book was released on 2004 with total page 1140 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Marco Weert
Publisher : Springer Science & Business Media
ISBN 13 : 0387758410
Total Pages : 269 pages
Book Rating : 4.3/5 (877 download)
Download or read book Immunogenicity of Biopharmaceuticals written by Marco Weert and published by Springer Science & Business Media. This book was released on 2008-02-06 with total page 269 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunogenicity of Biopharmaceuticals is the first book to comprehensively address the potential of an immune response to biopharmaceuticals. It is intended to give a broad overview of the current state-of-the-art regarding this subject. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.
Author : Peter Vaupel
Publisher : Lubrecht & Cramer, Limited
ISBN 13 :
Total Pages : 348 pages
Book Rating : 4.3/5 (91 download)
Download or read book Tumor Oxygenation written by Peter Vaupel and published by Lubrecht & Cramer, Limited. This book was released on 1995 with total page 348 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author :
Publisher :
ISBN 13 :
Total Pages : 81 pages
Book Rating : 4.:/5 (122 download)
Download or read book Emerging Therapies in Oncology Care written by and published by . This book was released on 1998 with total page 81 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Author : Hubert Schrezenmeier
Publisher : Cambridge University Press
ISBN 13 : 9780521641012
Total Pages : 410 pages
Book Rating : 4.6/5 (41 download)
Download or read book Aplastic Anemia written by Hubert Schrezenmeier and published by Cambridge University Press. This book was released on 2000 with total page 410 pages. Available in PDF, EPUB and Kindle. Book excerpt: Comprehensive and up-to-date clinical reference, with an emphasis on treatment.
Author : U. S. Department of Health and Human Services
Publisher : Createspace Independent Pub
ISBN 13 : 9781490386430
Total Pages : 394 pages
Book Rating : 4.3/5 (864 download)
Download or read book Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment written by U. S. Department of Health and Human Services and published by Createspace Independent Pub. This book was released on 2013-06-07 with total page 394 pages. Available in PDF, EPUB and Kindle. Book excerpt: This review compares the efficacy and adverse effects of specific erythropoietic stimulants (i.e., epoetin [alfa or beta], darbepoetin alfa) when used to manage anemia in patients undergoing cancer therapy (i.e., chemotherapy and/or radiation). This review also addresses questions relevant to optimizing the use of erythropoietic stimulants as a general class: the outcomes of using alternative thresholds to initiate or discontinue treatment and whether there are early predictors of response to treatment. Erythropoietin is an endogenous hormone, produced primarily in the kidney, which participates in regulating red blood cell production (erythropoiesis). Two forms of recombinant human erythropoietin—epoetin alfa and epoetin beta (the latter not commercially available in the United States)—have been extensively studied and used clinically for more than a decade to treat various anemias; they have similar clinical efficacy. In a recent review of safety concerns associated with recombinant human erythropoietins, a U.S. Food and Drug Administration (FDA) briefing document noted that “…the biochemical differences between various erythropoietin products are not associated with marked differences in the pharmacodynamic properties of the different products when used at recommended doses, thus effects observed with these non-US-licensed products may also be associated with the U.S. licensed product.” Anemia (deficiency of red blood cells) occurs in 13-78 percent of patients undergoing treatment for solid tumors and 30-40 percent of patients treated for lymphoma. Tumor type, treatment regimen, and history of prior cancer therapy influence the risk and severity of anemia. This report focuses on use of epoetin or darbepoetin to manage anemia in patients undergoing cancer treatment with chemotherapy and/or radiation. Anemia severity is defined by hemoglobin (Hb) concentration. Erythropoietin, a hormone produced primarily in the kidney, participates in regulating red blood cell production (erythropoiesis) and thus Hb concentration. Two erythropoietic stimulants are available commercially in the United States, epoetin alfa (Epogen®, Procrit®) and darbepoetin alfa (Aranesp®), which is a newer and longer acting drug. Epoetin beta, which is pharmacologically and clinically similar to epoetin alfa, is commercially available in Europe and elsewhere. Erythropoietic stimulants are widely used in clinical practice to manage anemia of patients undergoing cancer treatment and to reduce the need for transfusion. Although it is well established that erythropoietic stimulants improve anemia in patients undergoing cancer treatment, the comparative effectiveness of epoetin and darbepoetin has not been evaluated in a systematic review. Moreover, trials varied substantially in how erythropoietic stimulants have been used, including Hb concentration at start of treatment, doses given, treatment duration, and target Hb concentrations they sought to maintain. A review of these various trials may help maximize benefit, optimize drug usage, and minimize adverse effects from using erythropoietic stimulants to manage anemia in patients undergoing cancer treatment. The report addresses the following questions: 1. What are the comparative efficacy and safety of epoetin (alfa or beta) and darbepoetin? 2. How do alternative dosing strategies affect the comparative efficacy and safety of epoetin and darbepoetin? 3. How do alternative thresholds for initiating treatment or alternative criteria for discontinuing therapy or duration of therapy affect the efficacy and safety of erythropoietic stimulants? 4. Are any patient characteristics at baseline or early hematologic changes useful to select patients or predict responses to treatment with erythropoietic stimulants?
